PZRX.Q Stock Overview
A biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PhaseRx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | -99.00% |
| 5 Year Change | -99.90% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PZRX.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 1.0% |
| 1Y | n/a | 15.6% | 31.4% |
Return vs Industry: Insufficient data to determine how PZRX.Q performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PZRX.Q performed against the US Market.
Price Volatility
| PZRX.Q volatility | |
|---|---|
| PZRX.Q Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PZRX.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PZRX.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Robert Overell | n/a |
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency.
PhaseRx, Inc. Fundamentals Summary
| PZRX.Q fundamental statistics | |
|---|---|
| Market cap | US$11.00 |
| Earnings (TTM) | -US$13.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs PZRX.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PZRX.Q income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.89m |
| Earnings | -US$13.89m |
Last Reported Earnings
Sep 30, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PZRX.Q perform over the long term?
See historical performance and comparison